Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks

Ital J Pediatr. 2018 Aug 30;44(1):103. doi: 10.1186/s13052-018-0529-2.

Abstract

This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations.Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient's condition, and disease severity or individual complications.

Keywords: Aspirin; Child; Coronary artery abnormalities; Innovative biotechnologies; Intravenous immunoglobulin; Kawasaki disease; Personalized medicine.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / epidemiology
  • Child
  • Child, Preschool
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / epidemiology
  • Drug Resistance*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Male
  • Mucocutaneous Lymph Node Syndrome / diagnosis
  • Mucocutaneous Lymph Node Syndrome / drug therapy*
  • Mucocutaneous Lymph Node Syndrome / epidemiology
  • Pediatrics
  • Practice Guidelines as Topic*
  • Risk Assessment
  • Severity of Illness Index
  • Societies, Medical

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Immunoglobulins, Intravenous